From EP Impurities to Nitrosamines: A Complete Analysis of Tadalafil Impurity Control and Reference Standard Requirements

Tadalafil is a PDE5 inhibitor originally developed by Eli Lilly, mainly used to treat male erectile dysfunction (ED), with the official Chinese trade name "Cialis". Because its effect after a single dose can be maintained for a relatively long time — up to 36 hours — it is also figuratively called the "weekend pill."

However, for professionals in pharmaceutical quality, registration, and analytical development, this "old drug" that has been on the market for more than two decades is by no means "old" when it comes to impurity control. From routine process impurities to the nitrosamine impurities that have drawn intense regulatory attention in recent years, tadalafil covers many typical issues in API impurity research and control, and can be regarded as a condensed "textbook of API impurity control."

This article reviews, from a technical perspective, the pharmacopoeial impurity framework of tadalafil, the key points of nitrosamine compliance, and the practical demand for supporting reference standards.

1. What Kind of Drug Is Tadalafil?

Tadalafil is a selective phosphodiesterase type 5 (PDE5) inhibitor, which promotes relaxation of the corpus cavernosum and pulmonary vascular smooth muscle by inhibiting the breakdown of cGMP. According to information collected by the drug database Pharmacodia, tadalafil was originally developed by Eli Lilly and first approved for marketing in the EU in 2002; the US FDA approved it under the trade name Cialis for the treatment of erectile dysfunction in 2003, approved the 20 mg tablet (recommended daily dose 40 mg, i.e., 2 tablets) for the treatment of pulmonary arterial hypertension in 2009 (trade name Adcirca), and further expanded the Cialis indication to symptomatic benign prostatic hyperplasia in 2011. In China, its approved indications are erectile dysfunction and benign prostatic hyperplasia.

Tadalafil (Tadalafil, 171596-29-5)

The core skeleton of tadalafil is a pyrazinopyridoindole dione fused-ring structure containing a piperazinedione ring with a benzodioxole substituent. CAS number 171596-29-5, molecular formula C22H19N3O4, molecular weight approximately 389.4.

According to in vitro research data disclosed by Hepatox, the inhibitory effect of tadalafil on PDE5 is more than 10,000 times stronger than on PDE1, PDE2, PDE3, PDE4, and PDE7-10, and nearly 700 times stronger than on PDE6, which is involved in retinal phototransduction — this subtype selectivity is also one of the structural bases that distinguishes its clinical side-effect profile from that of similar drugs.

2. Impurity Control: The Logic Behind Pharmacopoeial Provisions

The core of an API quality standard has never been merely "meeting the content requirement," but rather the classification, naming, and limit control of all impurities, which are generally divided into process-related impurities (residual starting materials, intermediates, side-reaction products), degradation products, isomers, and genotoxic impurities that require separate assessment. The general chapters of the European Pharmacopoeia also align genotoxic impurity control with ICH M7 and elemental impurity control with ICH Q3D.

Tadalafil happens to be a molecule with a relatively complex impurity profile: its skeleton has two chiral centers, and during synthesis it is easy to form stereoisomers with exactly the same molecular formula as tadalafil but different spatial configurations — the EP impurities A, B, and C in the catalog are precisely such cases, all three having the molecular formula C22H19N3O4, identical to tadalafil itself; in addition, the synthetic route involves multiple condensation and ring-closure reactions, which may also leave oxidation/structurally modified impurities with extra oxygen atoms, as well as demethylene analogs (such as the separately named "demethylene tadalafil" in the catalog). This is why, around this single molecule, the industry has named and characterized more than one hundred known impurities.

3. The "Must-Answer Questions" in the European Pharmacopoeia Monograph

Tadalafil is included in the European Pharmacopoeia under monograph 2606 (Tadalafil). According to an academic paper published in ScienceDirect that conducted a "fingerprint" study on 46 batches of tadalafil API samples from 13 different manufacturers, in addition to routine items such as infrared spectroscopy identification, assay (97.5%–102.0%), and loss on drying (not more than 0.5%), the monograph also specifies tests for impurities A, B, and C and related substances: the limit for impurity A alone is not more than 0.15%, the limit for each other known or unknown impurity is not more than 0.10%, and total impurities not more than 0.3%.

European Pharmacopoeia Monograph 2606 Key Quality Requirements

▍European Pharmacopoeia Monograph 2606 (Tadalafil) — Key Quality Requirements

It is worth noting that this only covers the portion with explicit quantitative control in the version of the monograph on which that paper was based. Through cross-comparison of public product information from multiple international reference standard databases, the EP impurities with recognized names under tadalafil actually go far beyond A, B, and C — designations D, E, F, G, H, I, etc. have consistent CAS number and molecular formula records across different sources (for example, EP impurity A is confirmed to be the (6R,12aS) stereoisomer of tadalafil itself, and the molecular formulas of EP impurities D, E, F, and H are all C22H19N3O6, two oxygen atoms more than tadalafil). This suggests that relying only on the three impurity reference standards in the earlier monograph is no longer sufficient to cover today's more refined impurity profile comparison, method development, and registration filing needs; specific quantitative limits are still subject to the latest monograph text of the current edition of the pharmacopoeia.

4. An Unavoidable Red Line: Nitrosamine Impurities

If pharmacopoeial impurities are the "must-answer questions," nitrosamine impurities have in recent years been the "bonus questions" hanging over every API manufacturer.

This regulatory storm began in mid-2018: nitrosamine impurities such as N-nitrosodimethylamine (NDMA) were detected in valsartan API, and the European Medicines Agency (EMA) immediately initiated an assessment that was extended to a systematic review of all medicinal products for human use — nitrosamine compounds were classified as "probable human carcinogens" based on animal studies. The US FDA, together with international regulatory agencies, established the "Carcinogenic Potency Categorization Approach" (CPCA), which classifies carcinogenic potency based on structural features such as the number and distribution of α-hydrogen atoms in the molecule, to derive acceptable intake (AI) limits.

Nitrosamine regulatory event timeline (original image)

Why is tadalafil also on this risk list? Its piperazinedione structure retains a secondary amine (-NH-) group, which is one of the potential risk sources for nitrosamine impurity formation: once the secondary amine comes into contact with trace residues of nitrosating reagents such as nitrites during production or storage, the corresponding N-nitroso derivative may be formed. This is also why structures such as "N-nitrosotadalafil" and "tadalafil dinitroso impurity" are separately named and characterized.

The acceptable intake limits of nitrosamine impurities are usually at the nanogram-per-day level, which converts to ppm levels in the API concentration in most cases, and in some situations even approaches ppb. Routine HPLC-UV detection is no longer sufficient to meet the sensitivity requirement, and LC-MS/MS combined with isotope-labeled internal standards (deuterated, 13C-labeled) is generally needed for precise quantification — this is precisely why isotope-labeled products such as "tadalafil-d3," "tadalafil-13C2,d3," and "N-nitrosotadalafil-D3" exist.

5. CATO Provides the Tadalafil Reference Standard Series

Layering the requirements above together, for a laboratory to fully address the quality control and registration filing of tadalafil, the reference standards actually needed go far beyond simply "API + three EP impurities," and should cover at least:

• The API itself, plus reference standards for chromatographic system suitability/assay;

• Pharmacopoeially named impurities (A, B, C, and subsequent supplementary designations under EP/USP);

• Process-related impurities and degradation products, for method development and impurity profile assignment;

• Nitrosamine impurities and their isotope-labeled internal standards, for trace-level quantitative analysis;

• Isotope-labeled API itself, for metabolism, pharmacokinetic, or mass spectrometry internal standard studies.

▍CATO Tadalafil Series Reference Standard Product Table

(The above are some representative products; the complete product list can be obtained from CATO.)

As a reference material/reference sample producer that has passed both CNAS (RM0030) and ANAB (AR-2832) dual-system ISO 17034 accreditation, CATO provides HPLC, NMR, and MS triple structural confirmation for all tadalafil series reference standards, discloses a value assignment uncertainty of ±2.0% (95% CI) in the COA, ships in-stock specifications the same day, and supports custom synthesis for non-stock specifications, minimizing the waiting period for laboratories from "discovering an unknown peak" to "obtaining the reference standard."

Add CATO on WeChat · For details on tadalafil-related reference standards, please contact CATO

References

1. Pharmacodia drug database, tadalafil target/indication/first approval year information, https://data.pharmacodia.com/drugs/details/12002835551391696551

2. FierceBiotech, FDA Approves ADCIRCA (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension (approved May 2009, recommended daily dose 40 mg), https://www.fiercebiotech.com/...

3. FiercePharma, FDA approves Cialis to treat benign prostatic hyperplasia (approved for BPH indication October 2011), https://www.fiercepharma.com/...

4. Hepatox drug-induced liver injury network, tadalafil PDE subtype selectivity data, https://www.hepatox.org/drug/show/455

5. Pharmaceutical Data Center, tadalafil tablet product registration information (Chinese trade name "Cialis", English trade name Cialis), https://pharm.ncmi.cn/...

6. Clustering of Tadalafil API Samples According to their Manufacturer in the Context of API Falsification Detection, ScienceDirect (impurity A/B/C limit data for tadalafil European Pharmacopoeia monograph 2606), https://www.sciencedirect.com/...

7. Clearsynth, Tadalafil EP Impurity A product page ((6R,12aS) stereoisomer structure confirmation), https://clearsynth.com/...

8. European Medicines Agency (EMA), Nitrosamine impurities (regulatory background and guidance on nitrosamine impurities), https://www.ema.europa.eu/...

9. US FDA, Determining Recommended Acceptable Intake Limits for N-nitrosamine Impurities in Pharmaceuticals (CPCA carcinogenic potency categorization approach), https://www.fda.gov/...

10. Veeprho, Tadalafil Nitroso Impurity 5 product description (secondary amine structure and nitrosation site of tadalafil), https://veeprho.com/...

11. European Pharmacopoeia 10th ed. (alignment of general chapters with ICH M7 genotoxic impurities and ICH Q3D elemental impurities), https://dokumen.pub/...